Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma
Neoadjuvant therapy for advanced ATC appears to be a promising treatment approach for a subset of affected patients. While initial results are encouraging, further research is needed to establish its precise role within the multimodal management of this aggressive malignancy.
Authors
- Friederike Eilsberger (ORCID: https://orcid.org/0000-0003-3558-6817)
- Sabine Wächter (ORCID: https://orcid.org/0000-0003-3241-0728)
- Elisabeth Maurer (ORCID: https://orcid.org/0000-0003-3431-6233)
- Markus Luster
- Andreas Neubauer (ORCID: https://orcid.org/0000-0002-7606-8760)
- Katharina Holzer (ORCID: https://orcid.org/0000-0002-8258-3910)
- Detlef K. Bartsch (ORCID: https://orcid.org/0000-0003-2961-915X)
- Jorge Riera Knorrenschild
- Anika Pehl
- Andreas Pfestroff (ORCID: https://orcid.org/0000-0003-4209-4474)
Institutions
- Philipps University of Marburg (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.3389/fendo.2025.1619875
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- José Carreras Leukämie-Stiftung